Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 4:42 AM
Ignite Modification Date:
2025-12-26 @ 3:43 AM
NCT ID:
NCT04740918
Pre Assignment Details:
Participants were randomized in 1:1 ratio to receive trastuzumab emtansine + placebo or trastuzumab emtansine + atezolizumab.
Recruitment Details:
A total of 96 participants with human epidermal growth factor receptor 2 (HER2)-positive and programmed death-ligand 1 (PD-L1)-positive locally advanced (LABC) or metastatic breast cancer (MBC) took part in the study across 52 investigative sites in 19 countries from 07 June 2021 to 19 June 2024.
Study:
NCT04740918
Study Brief:
Results Section:
NCT04740918